Equities

Kanabo Group PLC

Kanabo Group PLC

Actions
Health CareHealth Care Providers
  • Price (GBX)1.30
  • Today's Change0.00 / 0.00%
  • Shares traded80.85k
  • 1 Year change-34.18%
  • Beta4.8941
Data delayed at least 20 minutes, as of Jul 26 2024 14:17 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Kanabo Group plc is a United Kingdom-based patient-focused provider of digital health services and specialist medicines, including medicinal cannabis. The Company’s principal activities are the distribution and development of cannabis derived medical and wellness products. The Company is focused on the distribution of cannabis-derived products for medical patients, and non- tetrahydrocannabinol (THC) products for cannabidiol (CBD) consumers. It has conducted research and development (R&D) in order to develop cannabis extract formulas, medical-grade vaporizers and various non-smoking consumption solutions. Its clinical and validation activities, including safety and efficiency tests, are conducted in Israel. The Company operates through two segments: Primary case and Secondary case. Primary case segment is involved in the telepharma services provided by GPS. Secondary case segment is involved in the distribution and development of cannabis-derived medical and wellness products.

  • Revenue in GBP (TTM)895.00k
  • Net income in GBP-7.99m
  • Incorporated2016
  • Employees17.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
N4 Pharma PLC1.95k-1.28m2.07m5.00--1.25--1,062.87-0.0053-0.00530.000010.00420.0011--0.009390.00-74.20-57.05-79.41-61.13-----65,475.90-309,312.80----0.00-----51.52-24.05------
CRISM' Therapeutics Corp0.00-1.86m4.40m4.00--0.3662-----0.2135-0.86160.000.3680.00----0.00-14.26-8.67-14.89-9.02-----------3.510.00------8.21------
BSF Enterprise PLC67.24k-1.71m5.43m4.00--1.36--80.68-0.0166-0.01660.00070.03870.01281.790.042516,810.00-32.47---34.78---44.74---2,542.56--6.17-218.850.0287-------61.40------
Oncimmune Holdings PLC1.21m-3.19m7.75m56.00------6.38-0.04270.09390.0163-0.01720.17561.190.6917---46.21------63.34---263.10--1.01-0.68151.32--------------
Kanabo Group PLC895.00k-7.99m8.22m17.00--1.09--9.19-0.0137-0.01370.00170.01190.078511.1128.4152,647.06-70.12-75.83-77.61-83.3314.97---893.30-1,267.354.96-10.430.035--48.42---16.26------
CRUSHMETRIC Group Ltd685.08k-6.66m30.00m20.00--1.62--43.78-0.0242-0.02420.00290.07720.02575.0817.96---25.36-25.22-30.89-56.6672.5841.64-985.69-200.760.0309-2.940.0814---36.42-8.40-1,096.05---29.47--
Data as of Jul 26 2024. Currency figures normalised to Kanabo Group PLC's reporting currency: UK Pound GBX
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.